Sofinnova Partners raised €333 million for its latest healthcare venture capital fund.
Sofinnova Capital IX will target the biopharmaceutical and medical device sectors. Two-thirds of the investments will be placed in European companies and a third in companies outside of Europe, primarily in North America.
Triago acted as placement agent, while Clifford Chance was the legal counsel.
Sofinnova Partners specializes in life sciences and makes investments across development stages.